Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...

Swiss drug major Novartis AG (NVS) reported Friday that its fourth-quarter net income plunged to $2.82 billion from last year's $8.48 ...

Novartis increased sales by 15 percent to USD 13.2 billion in the fourth quarter of 2024. Profit rose by 7 percent to USD 2.8 ...

Deliver returns: Continuing to embed operational excellence and deliver improved financials. Novartis remains disciplined and shareholder-focused in our approach to capital allocation, with ...

Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its ...

Japan is considering offering support for a $44 billion gas pipeline in Alaska as it seeks to court U.S. President Donald ...

Super Bowl LIX is already proving to offer serious star power, with ad spots led by Chris Pratt, Eugene Levy, Michelle ...

Novartis (NYSE:NVS) and MSN Pharmaceuticals have reached agreement in a Delaware federal court to dismiss patent litigation ...

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...

Coherus BioSciences, Inc.’s CHRS share price has surged by 10.66%, which has investors questioning if this is right time to sell.